Biotech China 2014
The 13th annual World Vaccine Congress Lyon is the vaccine conference addressing all major vaccine markets including Influenza, HPV, Pneumococcal and Meningococcal.
Palais des Congrès de Lyon
154, Grande Rue de St Clair, 69300 Caluire et Cuire, France
Caluire et Cuire, France
http://www.terrapinn.com/2011/world-vaccine-congress-lyon/index.stm
    *  Overcoming regulatory hurdles
    * Government vaccine strategies across Europe
    * Key developments in therapeutic and prophylactic vaccines
    * The future of Influenza vaccines
    * New strategies in the development of novel vaccines
    * Innovative approaches to funding in the vaccines market
    * The next generation of vaccines research and development across the board
    * The rise of open innovation and partnerships within the global vaccines industry

    *  The evolving nature of the vaccines market
    * Key disease focus areas, now and tomorrow
    * Innovation and ‘breaking boundaries’ within the vaccines market
    * Commercial strategies, including new partnership models
    * R&D paradigms and how innovation is shifting priorities in vaccines research
    * The responsibility to the developing world, and how philanthropic investment is driving new research and disease eradication programmes
    * Different scientific methods being applied to modern vaccine development
    * The changing regulatory landscape for influenza vaccines

    *  Pharmaceutical manufacturers
    * Large / SME Biotech
    * Government / Regulatory bodies
    * Academia / Research Institutes
    * Contract Research Organisations
    * Contract Manufacture Organisations
    * Equipment Manufacturers / Technology Providers
    * Investment Banks / Private Equity
    * Consultants

http://www.terrapinn.com/2011/world-vaccine-congress-lyon/index.stm

Schedule of Presentations:

Monday, October 10, 2011
07:55:00 NEW EUROPEAN AND REGULATORY BENCHMARKS FOR VACCINES
08:00:00 Registration and refreshments
09:00:00 Chairman’s opening remarks
09:15:00 New directions in EU vaccine research – some perspectives and prospects
09:45:00 Immunosafety of vaccines in the context of Innovative Medicines Initiative
10:15:00 ADITEC | A technology-based approach to vaccine research and development
10:45:00 The role of the European Vaccine Initiative today
11:10:00 A GOVERNMENTAL PERSPECTIVE – VACCINES STRATEGIES THROUGHOUT EUROPE
11:15:00 UK vaccine policy and strategy – adapting to change
11:20:00 Evolving immunisation program development and review Harald Heijbel
11:45:00 Morning refreshments
12:45:00 Taking action and a lead in coordinating public health Claire Boog
13:15:00 Question and answer session Claire Boog, Harald Heijbel
13:45:00 Networking lunch
14:40:00 PHARMA SPEAKS – FUTURE DEVELOPMENTS IN THE VACCINES MARKET
14:45:00 Understanding public trust in vaccination
15:15:00 Panel session | addressing significant unmet needs through world class vaccine pipelines
15:45:00 Enabling manufacture of modern vaccines
16:15:00 Afternoon refreshments
16:45:00 Panel session | how the vaccines market is changing and how Big Pharma is co-adapting Guido Grandi
17:05:00 THE ROLE OF NON-GOVERNMENT ORGANISATIONS IN EUROPE AND GLOBALLY
17:15:00 The role of MVI PATH and the responsibility to the developing world
17:45:00 The role of NGOs in Europe and globally Hansi Dean
18:15:00 Close of congress day one followed by networking drinks
Tuesday, October 11, 2011
08:55:00 VACCINES R&D – THE BIG PICTURE
09:00:00 Chairman’s opening remarks
09:10:00 Paradigm shifts | the future outlook for innovation in vaccines
09:40:00 Overcoming challenges in process development and manufacturing of vaccines for clinical trials
10:10:00 New European initiatives on vaccines
10:40:00 Morning refreshments
11:05:00 STREAM A | INFLUENZA – A CONSTANTLY EVOLVING CONCERN
11:05:00 STREAM B: THERAPEUTIC VACCINES - KEY DEVELOPMENTS
11:10:00 Review of the 2010 World Health Organization recommendations for influenza vaccination composition
11:10:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Chairman’s opening remarks
11:10:00 Chairman’s opening remarks Pamuk Bilsel
11:15:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Dendreon and Provenge update David Urdal
11:35:00 The changing regulatory landscape for influenza vaccines
11:40:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | ImmusanT’s development of an immunotherapeutic vaccine for celiac disease Leslie J. Williams
12:00:00 Ongoing risk assessments on Influenza Sports
12:10:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | PAMP-Adjuvants and the ongoing revolution in cancer immunotherapy – a TLR3 case study
12:25:00 'Flu programme' management within the UK
12:40:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Cocaine vaccine – new headway and developments Ronald Crystal
12:50:00 Communication efficacy across the vaccine delivery pipeline
13:10:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Networking lunch
13:15:00 Networking lunch
14:10:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | HPV-infected women before they develop cancer: the most favourable clinical setting to test a novel therapeutic vaccine technology
14:15:00 Case study for novel adjuvants as technology platforms – ISCOMATRIX® adjuvant Debbie Drane
14:40:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | HIV – after years of failure, what does the future hold for the Holy Grail of vaccines? Mark Bagarazzi
14:40:00 Adjuvants - a strategic component in modern vaccine
15:05:00 Human monoclonal antibodies against influenza: a map guiding towards a universal influenza vaccine? Jaap Goudsmit
15:10:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Anti-Ab active vaccine approaches for the treatment of Alzheimer’s disease
15:40:00 Intradermal Injections: Results of Phase I Intradermal Adaptor Study
15:40:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Q&A session- The future of novel therapeutic vaccines
16:00:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Speed Networking
16:00:00 Speed Networking
16:30:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Afternoon refreshments
16:30:00 Afternoon refreshments
17:00:00 Panel session | moving towards the reality of a universal influenza vaccine Sarah Gilbert, Jaap Goudsmit, Melissa Malhame
17:00:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Panel discussion: advancing Therapeutics through the clinic Mark Bagarazzi, Ronald Crystal, David Urdal
17:40:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Biotech showcase: universal influenza-A vaccine development and synthetic vaccines for mutating viruses Carlton Brown
17:45:00 Close of congress day two followed by networking drinks
18:00:00 STREAM B | THERAPEUTIC VACCINES - KEY DEVELOPMENTS | Close of congress day two followed by networking drinks
Wednesday, October 12, 2011
08:55:00 VACCINES R&D – THE BIG PICTURE
09:00:00 Chairman’s opening remarks
09:10:00 Immune-Stimulating Resistance-Inhibiting Cancer Vaccines John Rothman
09:40:00 Creating next generation novel vaccine platform in cancer and infection Ole Henrik Brekke
10:10:00 Advances and challenges in the development of novel cancer vaccines which may include data on the Stimuvax development
10:40:00 Morning refreshments
11:05:00 STREAM A: PROPHYLACTIC VACCINES MARKET - KEY DEVELOPMENTS
11:05:00 STREAM B: OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D
11:10:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | The rise of open innovation in drug discovery Marie Pierre de Bethune
11:10:00 Chairman’s opening remarks
11:10:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Chairman’s opening remarks
11:15:00 Vaccine Discovery: from “brute force” to high selectivity Guido Grandi
11:40:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Outsourcing in mature markets, offshoring in emerging markets
11:40:00 A new platform for new products in a new era
12:10:00 HIV vaccine – targeting transmission and infection events at the mucosal level Sylvain Fleury
12:10:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | In-licensing and partnering non-core assets with external vaccine parties: maximizing potential
12:40:00 Putting faith in potential market blockbusters; global meningococcal franchise development David G McIntosh
12:40:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Panel session | innovation evolution – what’s in it for Pharma? Marie Pierre de Bethune
13:10:00 Networking lunch
13:10:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Networking Lunch
14:10:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Use of a PBMC Network: successes and challenges
14:10:00 Novel vaccine fabrication – PRINT platform (Particle Replication in Non-Wetting Templates)
14:40:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Ensuring long-term growth in the emerging markets through achieving a localised presence
14:40:00 Ixiaro® - Japanese Encephalitis vaccine development, surpassing clinical hurdles and approval
15:10:00 RNA-based vaccines: a new approach to immunization
15:10:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | How important will developing markets be in the context of the global vaccine sector as whole?
15:40:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Afternoon Refreshments
15:40:00 Afternoon refreshments
16:10:00 Potent T-cell induction using chimpanzee derived adenovirus: progress towards an effective HCV vaccine
16:10:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | How a vaccine focused CRO can accelerate clinical trial
16:40:00 Developing a tetravalent vaccine to fully protect against all sub-types of Dengue virus
16:40:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Enabling innovation: novel bioconjugates for use in vaccines
17:10:00 Panel session | advancing Prophylactics through the clinic Sylvain Fleury, David McIntosh
17:40:00 STREAM B | OUTSOURCING AND OPEN INNOVATION IN VACCINES R&D | Close of congress day three
17:50:00 Close of congress day three
Thursday, October 13, 2011
08:55:00 CONFRONTING THE CHALLENGES OF ECONOMIC DOWNTURN
09:00:00 Chairman’s opening remarks Jean-Christophe Renondin, Managing Director - Healthcare, Bryan, Garnier & Co.
09:10:00 Investigate the impact of the economic downturn on the vaccine market Andrew Baum
09:35:00 NON DILUTIVE GOVERNMENTAL AND PHILANTHROPIC INVESTMENT
09:40:00 Non-dilutive funding sources in an economic time characterised by lack of funds
10:10:00 Enhancing research & development through innovative funding
10:40:00 Public/Private Partnerships – Beyond normal limits
11:10:00 Morning refreshments
11:35:00 DIFFERENT INVESTMENT SOURCES IN THE VACCINES MARKET
11:40:00 The VC model at a crossroads – where next? Gilles Nobecourt
12:10:00 Securing the right emerging market partnership for your platform
12:40:00 Proven strategy: the public/private partnership in action
13:10:00 Networking lunch
14:05:00 ENGAGING PRIVATE SECTOR FUNDING
14:10:00 Attracting private sector investment: minimise risk and increase confidence for the private sector and banks
14:40:00 VC regaining confidence after the financial crisis – an overview
15:10:00 Panel session | Investment or Partnership – What is the best deal for your company?
15:40:00 Close of congress
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.